The effects of Panax notoginseng on delayed onset muscle soreness and muscle damage in well-trained males: A double blind randomised controlled trial

Kate PUMPA, Kieran E. Fallon, Alan Bensoussan, Shona Papalia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: The aim of the study was to determine if Panax notoginseng is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improve performance in well trained males who underwent a bout of eccentric exercise designed to induce delayed onset muscle soreness (DOMS).

Design: A double blind randomised placebo controlled trial.

Setting: Twenty well trained male volunteers, matched by maximum aerobic capacity were randomly assigned to consume a regime of 4000 mg of P. notoginseng capsules or an indistinguishable placebo before and after a downhill treadmill running episode designed to induce DOMS.

Main outcome measures: Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale (VAS), algometer) and blood analyses (interleukin-1, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run).

Results: The placebo group demonstrated a significant decrease in squat jump performance immediately post the downhill run, with a mean change +/- 95% confidence interval (CI) of 0.8 cm (-3.53 to 1.93). The placebo group also experienced increased pain in the quadriceps 96 h after the downhill run, with a mean VAS change +/- 95% CI of -0.32 cm (-0.34 to 0.98).The serum concentration of IL-6 and TNF-alpha were significantly lower in the placebo group 24h after the downhill run. Mean IL-6 change +/- 95% CI of 0.50 pg/mL (-1.59 to 0.59), and mean TNF-alpha change +/- 95% CI was 0.98 pg/mL (-2.04 to 0.09). No other significant differences were identified between the groups for any other outcome measure.

Conclusion: Considering all data from this study, P. notoginseng did not convincingly have an effect on performance, muscular pain or assessed blood markers in well-trained males after an intense bout of eccentric exercise that induced DOMS
Original languageEnglish
Pages (from-to)131-140
Number of pages10
JournalComplementary Therapies in Medicine
Volume21
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Panax notoginseng
Myalgia
Randomized Controlled Trials
Placebos
Muscles
Confidence Intervals
Interleukin-6
Tumor Necrosis Factor-alpha
Visual Analog Scale
Pain
Lymphotoxin-beta
Outcome Assessment (Health Care)
Myoglobin
Pain Measurement
Creatine Kinase
Interleukin-1
Running
C-Reactive Protein
Capsules
Volunteers

Cite this

@article{6ec371b552ce4062bb44d76969d8a940,
title = "The effects of Panax notoginseng on delayed onset muscle soreness and muscle damage in well-trained males: A double blind randomised controlled trial",
abstract = "Objectives: The aim of the study was to determine if Panax notoginseng is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improve performance in well trained males who underwent a bout of eccentric exercise designed to induce delayed onset muscle soreness (DOMS). Design: A double blind randomised placebo controlled trial. Setting: Twenty well trained male volunteers, matched by maximum aerobic capacity were randomly assigned to consume a regime of 4000 mg of P. notoginseng capsules or an indistinguishable placebo before and after a downhill treadmill running episode designed to induce DOMS. Main outcome measures: Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale (VAS), algometer) and blood analyses (interleukin-1, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run). Results: The placebo group demonstrated a significant decrease in squat jump performance immediately post the downhill run, with a mean change +/- 95{\%} confidence interval (CI) of 0.8 cm (-3.53 to 1.93). The placebo group also experienced increased pain in the quadriceps 96 h after the downhill run, with a mean VAS change +/- 95{\%} CI of -0.32 cm (-0.34 to 0.98).The serum concentration of IL-6 and TNF-alpha were significantly lower in the placebo group 24h after the downhill run. Mean IL-6 change +/- 95{\%} CI of 0.50 pg/mL (-1.59 to 0.59), and mean TNF-alpha change +/- 95{\%} CI was 0.98 pg/mL (-2.04 to 0.09). No other significant differences were identified between the groups for any other outcome measure. Conclusion: Considering all data from this study, P. notoginseng did not convincingly have an effect on performance, muscular pain or assessed blood markers in well-trained males after an intense bout of eccentric exercise that induced DOMS",
keywords = "Acute phase response, DOMS, Exercise, Muscle damage, Panax notoginseng, Recovery",
author = "Kate PUMPA and Fallon, {Kieran E.} and Alan Bensoussan and Shona Papalia",
year = "2013",
doi = "10.1016/j.ctim.2012.12.007",
language = "English",
volume = "21",
pages = "131--140",
journal = "Complementary Medical Research",
issn = "0965-2299",
publisher = "Churchill Livingstone",
number = "3",

}

The effects of Panax notoginseng on delayed onset muscle soreness and muscle damage in well-trained males: A double blind randomised controlled trial. / PUMPA, Kate; Fallon, Kieran E.; Bensoussan, Alan; Papalia, Shona.

In: Complementary Therapies in Medicine, Vol. 21, No. 3, 2013, p. 131-140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of Panax notoginseng on delayed onset muscle soreness and muscle damage in well-trained males: A double blind randomised controlled trial

AU - PUMPA, Kate

AU - Fallon, Kieran E.

AU - Bensoussan, Alan

AU - Papalia, Shona

PY - 2013

Y1 - 2013

N2 - Objectives: The aim of the study was to determine if Panax notoginseng is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improve performance in well trained males who underwent a bout of eccentric exercise designed to induce delayed onset muscle soreness (DOMS). Design: A double blind randomised placebo controlled trial. Setting: Twenty well trained male volunteers, matched by maximum aerobic capacity were randomly assigned to consume a regime of 4000 mg of P. notoginseng capsules or an indistinguishable placebo before and after a downhill treadmill running episode designed to induce DOMS. Main outcome measures: Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale (VAS), algometer) and blood analyses (interleukin-1, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run). Results: The placebo group demonstrated a significant decrease in squat jump performance immediately post the downhill run, with a mean change +/- 95% confidence interval (CI) of 0.8 cm (-3.53 to 1.93). The placebo group also experienced increased pain in the quadriceps 96 h after the downhill run, with a mean VAS change +/- 95% CI of -0.32 cm (-0.34 to 0.98).The serum concentration of IL-6 and TNF-alpha were significantly lower in the placebo group 24h after the downhill run. Mean IL-6 change +/- 95% CI of 0.50 pg/mL (-1.59 to 0.59), and mean TNF-alpha change +/- 95% CI was 0.98 pg/mL (-2.04 to 0.09). No other significant differences were identified between the groups for any other outcome measure. Conclusion: Considering all data from this study, P. notoginseng did not convincingly have an effect on performance, muscular pain or assessed blood markers in well-trained males after an intense bout of eccentric exercise that induced DOMS

AB - Objectives: The aim of the study was to determine if Panax notoginseng is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improve performance in well trained males who underwent a bout of eccentric exercise designed to induce delayed onset muscle soreness (DOMS). Design: A double blind randomised placebo controlled trial. Setting: Twenty well trained male volunteers, matched by maximum aerobic capacity were randomly assigned to consume a regime of 4000 mg of P. notoginseng capsules or an indistinguishable placebo before and after a downhill treadmill running episode designed to induce DOMS. Main outcome measures: Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale (VAS), algometer) and blood analyses (interleukin-1, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run). Results: The placebo group demonstrated a significant decrease in squat jump performance immediately post the downhill run, with a mean change +/- 95% confidence interval (CI) of 0.8 cm (-3.53 to 1.93). The placebo group also experienced increased pain in the quadriceps 96 h after the downhill run, with a mean VAS change +/- 95% CI of -0.32 cm (-0.34 to 0.98).The serum concentration of IL-6 and TNF-alpha were significantly lower in the placebo group 24h after the downhill run. Mean IL-6 change +/- 95% CI of 0.50 pg/mL (-1.59 to 0.59), and mean TNF-alpha change +/- 95% CI was 0.98 pg/mL (-2.04 to 0.09). No other significant differences were identified between the groups for any other outcome measure. Conclusion: Considering all data from this study, P. notoginseng did not convincingly have an effect on performance, muscular pain or assessed blood markers in well-trained males after an intense bout of eccentric exercise that induced DOMS

KW - Acute phase response

KW - DOMS

KW - Exercise

KW - Muscle damage

KW - Panax notoginseng

KW - Recovery

U2 - 10.1016/j.ctim.2012.12.007

DO - 10.1016/j.ctim.2012.12.007

M3 - Article

VL - 21

SP - 131

EP - 140

JO - Complementary Medical Research

JF - Complementary Medical Research

SN - 0965-2299

IS - 3

ER -